The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients

Waleed Albaker,1 Mona Al Sheikh,2 Aishah Albakr,3 Dania Alkhafaji,1 Eman Al Besher,4 Mohammed Al-Hariri2 1Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 2Department of Physiology, College of Medicine, Imam Abdulrahman Bin Faisal Un...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Albaker W, Al Sheikh M, Albakr A, Alkhafaji D, Al Besher E, Al-Hariri M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	obesity liraglutide weight loss saudi. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/0d4b22a63b744e2a91bd77541eb7cbf6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0d4b22a63b744e2a91bd77541eb7cbf6
record_format	dspace
spelling	oai:doaj.org-article:0d4b22a63b744e2a91bd77541eb7cbf62021-11-23T18:43:01ZThe Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients1178-7074https://doaj.org/article/0d4b22a63b744e2a91bd77541eb7cbf62021-11-01T00:00:00Zhttps://www.dovepress.com/the-efficacy-and-safety-of-liraglutide-30-mg-for-weight-management-in--peer-reviewed-fulltext-article-IJGMhttps://doaj.org/toc/1178-7074Waleed Albaker,1 Mona Al Sheikh,2 Aishah Albakr,3 Dania Alkhafaji,1 Eman Al Besher,4 Mohammed Al-Hariri2 1Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 2Department of Physiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 3Department of Neurology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 4Department of Family Medicine, Ministry of Health, Dammam, Saudi ArabiaCorrespondence: Mohammed Al-HaririDepartment of Physiology, College of Medicine, Imam Abdulrahman Bin Faisal University, P.O. Box 2114-31451, Dammam, Saudi ArabiaTel +966 50-727-5028Email mtalhariri@iau.edu.saBackground: Unmanaged cases of obesity might lead to serious conditions and complications, which impair patients’ lives. The aim of this study was to assess the effectiveness and safety of daily 3 mg subcutaneous (s/c) Liraglutide amongst obese non-diabetic patients in Eastern Province, Saudi Arabia.Methods: A retrospective cohort study of obese non-diabetic Saudi patients with obesity managed with s/c Liraglutide 3.0 mg who visited the outpatient clinic in Al Mashfa Hospital, Al Khobar, KSA during 2019– 2021. We collected patient data from the electronic reporting system for different parameters. Body weight, hemoglobin A1c %, systolic and diastolic blood pressure mmHg were obtained at baseline and after the intervention.Results: Records of 258 patients who were using a daily dose of Liraglutide 3.0 mg s/c for at least four months have been reviewed. The body weight loss of patients who used Liraglutide for four months was 8.1± 0.8 kg. Moreover, around 204 patients continued for up to six months. Meanwhile, the mean body weight loss was 13 kg. There was a significant reduction of hemoglobin A1c (HbA1c) % by 0.43%. The majority of patients (94.5%) reported satisfaction with the treatment, while adverse events were mainly nausea, vomiting and constipation.Conclusion: Daily s/c Liraglutide of 3.0 mg is effective in producing significant body weight reduction in obese non-diabetic Saudi patients with tolerable minimal side effects and may provide health benefits in terms of reduced risk of obesity and its related outcomes.Keywords: obesity, Liraglutide, weight loss, SaudiAlbaker WAl Sheikh MAlbakr AAlkhafaji DAl Besher EAl-Hariri MDove Medical Pressarticleobesityliraglutideweight losssaudi.Medicine (General)R5-920ENInternational Journal of General Medicine, Vol Volume 14, Pp 8643-8650 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	obesity liraglutide weight loss saudi. Medicine (General) R5-920
spellingShingle	obesity liraglutide weight loss saudi. Medicine (General) R5-920 Albaker W Al Sheikh M Albakr A Alkhafaji D Al Besher E Al-Hariri M The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
description	Waleed Albaker,1 Mona Al Sheikh,2 Aishah Albakr,3 Dania Alkhafaji,1 Eman Al Besher,4 Mohammed Al-Hariri2 1Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 2Department of Physiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 3Department of Neurology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 4Department of Family Medicine, Ministry of Health, Dammam, Saudi ArabiaCorrespondence: Mohammed Al-HaririDepartment of Physiology, College of Medicine, Imam Abdulrahman Bin Faisal University, P.O. Box 2114-31451, Dammam, Saudi ArabiaTel +966 50-727-5028Email mtalhariri@iau.edu.saBackground: Unmanaged cases of obesity might lead to serious conditions and complications, which impair patients’ lives. The aim of this study was to assess the effectiveness and safety of daily 3 mg subcutaneous (s/c) Liraglutide amongst obese non-diabetic patients in Eastern Province, Saudi Arabia.Methods: A retrospective cohort study of obese non-diabetic Saudi patients with obesity managed with s/c Liraglutide 3.0 mg who visited the outpatient clinic in Al Mashfa Hospital, Al Khobar, KSA during 2019– 2021. We collected patient data from the electronic reporting system for different parameters. Body weight, hemoglobin A1c %, systolic and diastolic blood pressure mmHg were obtained at baseline and after the intervention.Results: Records of 258 patients who were using a daily dose of Liraglutide 3.0 mg s/c for at least four months have been reviewed. The body weight loss of patients who used Liraglutide for four months was 8.1± 0.8 kg. Moreover, around 204 patients continued for up to six months. Meanwhile, the mean body weight loss was 13 kg. There was a significant reduction of hemoglobin A1c (HbA1c) % by 0.43%. The majority of patients (94.5%) reported satisfaction with the treatment, while adverse events were mainly nausea, vomiting and constipation.Conclusion: Daily s/c Liraglutide of 3.0 mg is effective in producing significant body weight reduction in obese non-diabetic Saudi patients with tolerable minimal side effects and may provide health benefits in terms of reduced risk of obesity and its related outcomes.Keywords: obesity, Liraglutide, weight loss, Saudi
format	article
author	Albaker W Al Sheikh M Albakr A Alkhafaji D Al Besher E Al-Hariri M
author_facet	Albaker W Al Sheikh M Albakr A Alkhafaji D Al Besher E Al-Hariri M
author_sort	Albaker W
title	The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
title_short	The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
title_full	The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
title_fullStr	The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
title_full_unstemmed	The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
title_sort	efficacy and safety of liraglutide 3.0 mg for weight management in obese non-diabetic saudi outpatients
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/0d4b22a63b744e2a91bd77541eb7cbf6
work_keys_str_mv	AT albakerw theefficacyandsafetyofliraglutide30mgforweightmanagementinobesenondiabeticsaudioutpatients AT alsheikhm theefficacyandsafetyofliraglutide30mgforweightmanagementinobesenondiabeticsaudioutpatients AT albakra theefficacyandsafetyofliraglutide30mgforweightmanagementinobesenondiabeticsaudioutpatients AT alkhafajid theefficacyandsafetyofliraglutide30mgforweightmanagementinobesenondiabeticsaudioutpatients AT albeshere theefficacyandsafetyofliraglutide30mgforweightmanagementinobesenondiabeticsaudioutpatients AT alharirim theefficacyandsafetyofliraglutide30mgforweightmanagementinobesenondiabeticsaudioutpatients AT albakerw efficacyandsafetyofliraglutide30mgforweightmanagementinobesenondiabeticsaudioutpatients AT alsheikhm efficacyandsafetyofliraglutide30mgforweightmanagementinobesenondiabeticsaudioutpatients AT albakra efficacyandsafetyofliraglutide30mgforweightmanagementinobesenondiabeticsaudioutpatients AT alkhafajid efficacyandsafetyofliraglutide30mgforweightmanagementinobesenondiabeticsaudioutpatients AT albeshere efficacyandsafetyofliraglutide30mgforweightmanagementinobesenondiabeticsaudioutpatients AT alharirim efficacyandsafetyofliraglutide30mgforweightmanagementinobesenondiabeticsaudioutpatients
_version_	1718416135913734144

The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients

Ejemplares similares